Biomedtracker and Meddevicetracker Q3 2016 Outlook Report

July 19, 2016

<img src="http://www.citeline.com/wp-content/uploads/Q3-2016-Outlook-Report_landing-page-banner.png" alt="Outlook report banner (1)" class="alignleft size-full wp-image-17172" /> <BR><BR> In this report, we cover catalysts from 24 drugs, devices and diagnostics expected to occur in Q3 2016. We have also included a list of Large Impact catalysts in the drug and device/diagnostic areas through Q3 2016. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. <BR><BR> This report includes a summary of high-impact catalysts highlighted in Q2 2016 Outlook Report. Biomedtracker’s Likelihood of Approval (LOA) opinions successfully predicted 63% of catalyst outcomes that occurred in Q2 2016. <BR><BR> <BR><BR> You may also be interested in FREE sample of: <ul> <li><A href="http://www.biomedtracker.com/FreeReportDetail.cfm?ReportID=661">The Intersection Between Tech and Pharma Special Report (Part 1. Google)</a> </ul> <BR><BR> To purchase Parts 2 and 3, please visit the linked pages. <ul> <li><A href="http://www.biomedtracker.com/FreeReportDetail.cfm?ReportID=664">The Intersection Between Tech and Pharma Special Report (Part 2. Apple)</a> <li><A href="http://www.biomedtracker.com/FreeReportDetail.cfm?ReportID=668">The Intersection Between Tech and Pharma Special Report (Part 3. Intel, Samsung, IBM, and GE)</a> </ul>